ALK and non-small cell lung carcinoma: Treatment after acquired resistance to ALK inhibitors include other ALK inhibitors, but an immune checkpoint inhibitor (ICI) + chemotherapy, which is the standard first-line treatment for NSCLC without a driver oncogene, is a candidate for ALK inhibitor resistance.